Assessing the epidemiological impact of *Wolbachia* deployment for dengue control

Louis Lambrechts, PhD,^{1*} Prof. Neil M. Ferguson, PhD,² Eva Harris, PhD,³ Prof. Edward C. Holmes, PhD,⁴ Elizabeth A. McGraw, PhD,⁶ Prof. Scott L. O'Neill, PhD,⁶ Eng E. Ooi, PhD,⁷ Prof. Scott A. Ritchie, PhD,⁸ Peter A. Ryan, PhD,⁶ Prof. Thomas W. Scott, PhD,^{9,10} Prof. Cameron P. Simmons, PhD,^{11,12,13} Prof. Scott C. Weaver, PhD¹⁴

¹ *Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur – CNRS URA 3012, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France*

² *MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, United Kingdom*

³ *Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 185 Li Ka Shing Center, Berkeley, CA 94720-3370, USA*

⁴ *Marie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Biological Sciences and Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia*

⁶ *School of Biological Sciences, Monash University, Clayton VIC 3800, Australia*

⁷ *Program in Emerging Infectious Diseases, Duke-National University of Singapore Graduate Medical School, 8 College Road, Singapore 169857*

⁸ *School of Public Health and Tropical Medicine and Rehabilitative Sciences, James Cook University, Cairns Queensland 4870, Australia*

⁹ *Department of Entomology and Nematology, University of California, Davis, CA 95695, USA*

¹⁰ *Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA*

27 ¹¹ *Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City,*
28 *District 5, Vietnam*

29 ¹² *Centre for Tropical Medicine, Nuffield Department of Medicine, University of*
30 *Oxford, Oxford OX1 2JD, United Kingdom*

31 ¹³ *Nossal Institute of Global Health, University of Melbourne, Carlton, VIC 3010, Australia*

32 ¹⁴ *Institute for Human Infections and Immunity and Department of Pathology, University of*
33 *Texas Medical Branch, Galveston, TX 77555-0610, USA*

34

35 ** Corresponding author. Telephone: +33140613497. E-mail: louis.lambrechts@pasteur.fr*

36

Summary

Dengue viruses cause more human morbidity and mortality than any other arthropod-borne virus. Dengue prevention relies primarily on vector control but the failure of traditional methods has promoted the development of novel entomological approaches. Although use of the intracellular bacterium *Wolbachia* to control mosquito populations was proposed half a century ago, it has only gained significant interest as a potential agent of dengue control in the last decade. Here, we review the evidence that supports a practical approach for dengue reduction through field release of *Wolbachia*-infected mosquitoes and discuss the additional studies that must be conducted before the strategy can be validated and operationally implemented. A critical next step is to assess the efficacy of *Wolbachia* deployment in reducing dengue virus transmission. We argue that a cluster-randomized trial is currently premature because *Wolbachia* strain choice for release as well as deployment strategies are still being optimized. We therefore present a pragmatic approach to acquiring preliminary evidence of efficacy via a suite of complementary methodologies: prospective cohort study, geographical cluster investigation, virus phylogenetic analysis, virus surveillance in mosquitoes, and vector competence assays. This multi-pronged approach could provide valuable intermediate evidence of efficacy to justify a future cluster-randomized trial.

Dengue is a major public health problem in tropical and sub-tropical regions, where almost 400 million infections are estimated to occur each year.¹ The etiological agents are four dengue virus serotypes (DENV-1 to -4) in the genus *Flavivirus* that are transmitted among humans by mosquitoes. These viruses cause a systemic, debilitating though mostly self-limiting illness, which without careful management can lead to hypovolemic shock and death.² In the absence of a licensed vaccine or therapeutic drug, dengue prevention efforts are currently limited to the control of its main mosquito vector, *Aedes aegypti*. With a few exceptions, the implementation of vector control methods has been largely unsuccessful due to the lack of sustained commitment of resources³ and inability to effectively scale-up and successfully apply interventions over large geographic areas and modern mega-cities. Novel entomological approaches to dengue control have been developed⁴ and some are now advancing to field testing.⁵

***Wolbachia*-based strategies for dengue control**

One of the most promising entomological strategies being developed for dengue control relies on introduction of the intracellular bacterium *Wolbachia* into *Ae. aegypti*.⁶ *Wolbachia pipientis* is a bacterial endosymbiont that was originally identified in ovaries of *Culex* mosquitoes in the 1920s⁷ and is thought to infect two-thirds of all living insect species.⁸ The extraordinary evolutionary success of *Wolbachia* is attributed to their ability to manipulate the biology of their hosts in diverse ways.⁹ For example, *Wolbachia* can induce reproductive abnormalities such as feminization and sperm-egg cytoplasmic incompatibility (CI). Because *Wolbachia* is transmitted vertically via the egg, these female-biased reproductive manipulations can drive *Wolbachia* infections to high frequencies in wild populations. CI, the most common manipulation in insects, occurs when *Wolbachia*-infected males mating with *Wolbachia*-free females lead to the production of non-viable offspring. *Wolbachia*-infected

females, in contrast, produce successful offspring regardless of the *Wolbachia* infection status of their mate.

The potential of *Wolbachia* to control pest insect populations was realized as early as half a century ago (Figure 1). *Wolbachia*-induced CI was then proposed to eliminate *Culex* mosquitoes¹⁰ or to introduce desirable genes into wild vector populations.¹¹ To date, however, *Wolbachia* have never been operationally implemented as a vector control measure. A significant hurdle was the fact that several major vectors of human pathogens are not naturally infected by *Wolbachia*, including the main DENV vector *Ae. aegypti*. The mosquito vectors (*Anopheles* spp.) of human malaria parasites were also thought to be *Wolbachia*-free until a recent study reported evidence for *Wolbachia* in field populations of *An. gambiae*.¹²

A resurgence of interest for *Wolbachia*-based strategies to control vector-borne diseases occurred about a decade ago with the advent of transinfection techniques (Figure 1). Stable *Wolbachia* infections in naïve hosts can now be established by embryonic microinjections into the developing embryo germline. In general, *Wolbachia* transinfection is more likely to be successful between closely related donor and recipient hosts, and the expression of *Wolbachia*-induced phenotypes is conserved across hosts. In 2005, a stable infection by a *Wolbachia* strain from the mosquito *Aedes albopictus* was established in *Ae. aegypti*, which caused high rates of CI and rapidly spread to high frequencies in experimental populations.¹³ This was quickly followed by double transinfections of *Ae. aegypti* with two different *Wolbachia* strains from *Ae. albopictus*.¹⁴

A second wave of breakthroughs occurred a few years later with the discovery of *Wolbachia*-induced phenotypes in mosquitoes that had a direct effect on pathogen transmission (Figure 1). Until then *Wolbachia* was primarily considered a gene drive system, but the possibility to transinfect *Wolbachia* strains from more distant hosts by cell culture adaptation prior to

microinjection,¹⁵ combined with the wide diversity of available *Wolbachia* strains and properties, resulted in new mosquito-*Wolbachia* associations. Stable introduction of a life-shortening strain of *Wolbachia* from *Drosophila* into *Ae. aegypti* halved the adult mosquito life-span under laboratory conditions, making mosquitoes unlikely to live long enough to transmit DENV.¹⁶ More importantly, this life-shortening *Wolbachia* strain directly inhibited the ability of a range of pathogens, including DENV, to infect and replicate in *Ae. aegypti*.¹⁷ Finally, semi-field and field trials in Australia demonstrated that *Wolbachia* can be persistently established in wild *Ae. aegypti* populations.^{18,19} Together, these properties form the basis of a practical approach for suppression of DENV transmission through field release of *Wolbachia*-infected mosquitoes.

Current status of *Wolbachia* deployment for dengue control

The critical next step is to assess the efficacy of medium-scale *Wolbachia* deployment in reducing human DENV infection. The gold standard, a cluster-randomized trial (CRT) of *Wolbachia*, has been considered in detail previously.²⁰ CRT is a type of randomized controlled trial in which groups of subjects, instead of individual subjects, are randomly assigned to the alternative treatments under study. The CRT design is particularly useful when the intervention cannot be directed toward selected individual subjects, such as the release of *Wolbachia*-infected mosquitoes. In the classical two-armed CRT, clusters without intervention provide contemporaneous controls. In a stepped wedge CRT, the intervention is rolled-out sequentially to all the clusters so that the clusters are their own controls over time.

We believe that at this time a CRT is premature for the *Wolbachia*-based approach for several reasons. First, there are multiple strains of *Wolbachia* available for deployment, each with its own characteristic effects on DENV blocking and mosquito fitness. A process of selection through field-testing is still required before one or more final strain(s) can be chosen

for a particular release area. In addition, while deployment in North Queensland has provided a basic template for release, this environment differs substantially from the large urban centers in Southeast Asia and Latin America where a CRT would likely be carried out. It is crucial to retain the capacity to learn during deployment about the effectiveness of release strategies and community engagement and to adjust practice accordingly. Past examples of adaptive changes made during deployment include releasing larger numbers of mosquitoes, changing the intensity of trap grids to monitor *Wolbachia* spread, supplementing releases with different mosquito developmental stages, and altering locations of deployment based on community concerns.^{18,21} In contrast, the standard CRT approach would lock-in all aspects of the release, preventing ‘on the fly’ improvements in design. Finally, a classical two-armed CRT would have to be large, with >40 clusters that each include approximately 100 study subjects who are monitored for infection to detect a 50% reduction in dengue with 90% power.²⁰ Rough estimates of cost for such a design suggest it would exceed 5-10 million USD.

A pragmatic approach to optimize *Wolbachia* deployment

Here, we argue that well-designed observational studies could provide a suite of valuable indirect evidence that supports *Wolbachia* as a dengue intervention and, hence, justifies continued development, ultimately leading to a definitive efficacy trial. Ideally, several observational studies would be conducted in different settings and their outcomes combined in a meta-analytic framework to assess the impact on disease and infection incidence. Below we describe five possible approaches that could be used separately or in combination for acquiring such evidence.

Pediatric cohort study. A prospective longitudinal cohort study that tracks seroconversion rates in children could measure both the true incidence of DENV infections and the relative

risk of infection between *Wolbachia*-treated and untreated areas.²⁰ Because the overall DENV seroconversion rate is generally 5-10% per annum in endemic countries,²² a cohort would need to include at least several thousand individuals to be compatible with the statistical requirements of a CRT with sufficient power to detect a moderate intervention effect.²⁰ A smaller cohort of 1,000-1,500 children, although underpowered in the context of a CRT, could be significantly enhanced by the concurrent approaches described below. Fine-scale entomological surveillance (e.g., a grid of traps) would allow monitoring the spatio-temporal dynamics of *Wolbachia* prevalence to distinguish, in real time, *Wolbachia*-free areas from areas where *Wolbachia* had established. The raw entomological data could be interpolated over time and space using standard methodology and serve as a covariate for DENV seroconversion. As in other epidemiological investigations, participants residing in the study area, but acquiring infections outside of the intervention area, represent a complication to this approach.^{23,24} However, geographical cluster studies of dengue cases and fine-scale spatiotemporal phylogenetic analyses of genomic DENV strain sequences (see below) would help to address this concern.

Geographical cluster investigation. DENV infections are acute, often mild, inapparent or with non-specific signs and symptoms, and thus are difficult to detect across populations in real time. Active surveillance of human infections can be efficiently achieved using geographical cluster sampling around dengue index cases.^{25,26} Here, 'index case' refers to the laboratory-diagnosed clinical dengue case that initiates a cluster investigation within a geographically restricted area around the home of a person with a documented DENV infection. Geographical cluster investigations could be used to compare the fine-scale spatial signature of DENV transmission in areas with and without *Wolbachia* (Figure 2). This methodology would test the hypothesis that concurrent and/or subsequent infections around an index case are reduced in areas where *Wolbachia*-infected mosquitoes are established. Inward migration of dengue infections acquired outside the treatment area would also be a confounding factor,^{23,24} although again potentially resolvable through detailed phylogenetic

analysis of virus sequences and/or monitoring movement patterns of study participants. Nonetheless, if a *Wolbachia* intervention reduces local transmission at a micro-scale, it should be detectable by a cluster investigation methodology. An efficacious intervention would result in a lower overall number of index cases in the *Wolbachia*-treated areas and/or reduction in concurrent infections measured by a lower frequency of cases that are spatiotemporally linked to the index case.

Virus sequence analysis. Increasing access to viral genome sequence data has promoted the development of new methodologies to infer dengue epidemiological dynamics based on analyses of changing patterns in viral genetic diversity in time and space.^{27,28} Assuming that multiple lineages of various DENV serotypes co-circulate prior to an intervention, a reduction in local DENV transmission is expected to result in a decrease in viral genetic diversity across serotypes in the intervention area due to a major viral demographic bottleneck, and in an increase in the average dispersion distances travelled by DENV into the intervention area (Figure 3). Phylogenetic analysis provides a simple means to identify importation of ‘foreign’ viral lineages into the study area, provided that genetic diversity accumulates at a sufficiently high rate. Previous studies on DENV microevolution in Southeast Asia suggested that spatial patterns of genetic diversity are shaped by frequent virus immigration and highly focal transmission.²⁸⁻³⁰ Although the level of phylogenetic resolution to be obtained is uncertain, deep sequencing methods have recently undergone dramatic improvement, increasing the power of this approach. We expect that if local DENV transmission is reduced in *Wolbachia*-treated areas, some viruses will continue to be imported by human-mediated dispersal but will not persist locally, reducing the strong spatial clustering that is typically observed in DENV phylogenies.

Virus detection in mosquitoes. The release of *Wolbachia*-infected mosquitoes will require monitoring of the local *Ae. aegypti* population for changes in *Wolbachia* frequency and possibly in mosquito density. Recently, several sampling methods that effectively capture

female *Ae. aegypti* have been developed.³¹⁻³⁴ Virus detection could be combined with routine molecular tests for *Wolbachia* presence. Detecting DENV-infected *Ae. aegypti* mosquitoes is challenging because of the low infection rates (typically ~0.1%) in the adult females across the population, although infection rates can be higher in locations of geographical cluster investigations.²⁵ Because mosquitoes that test positive for virus are not necessarily infectious, the proportion of DENV-infected mosquitoes does not directly translate into an estimate of virus transmission unless virus disseminated from the mosquito midgut or in saliva is also assayed, and even this approach is limited by the sensitivity of assays and variation of *in vitro* saliva collections. Nonetheless, a successful intervention is expected to reduce the incidence of viremic and infectious humans and, therefore, similarly reduce the incidence of DENV infection in mosquitoes in areas where *Wolbachia* infection predominates.

Vector competence assays. Following the release of *Wolbachia*-infected mosquitoes, it will be necessary to verify that the phenotype of reduced vector competence is maintained over time in field-collected mosquitoes.³⁵ Vector competence assays consist of experimentally exposing laboratory-reared mosquitoes to either an artificial infectious blood meal or the blood of a viremic person.³⁶ The proportion of infectious mosquitoes (i.e., with virus detected in saliva) is then measured over time. *Wolbachia*-infected mosquitoes have a strongly reduced ability to deliver DENV in their saliva compared to *Wolbachia*-free mosquitoes.¹⁹ Ideally, vector competence experiments would be extended to human-to-mosquito-to-human transmission experiments in a human challenge model.³⁷ Vector competence assays will provide additional indirect evidence on the impact of the intervention, especially if the virus interference effect is strong.

Conclusions and perspectives

The current challenge is to convert a promising strategy into a validated public health intervention through rigorous assessment of its epidemiological impact. The suite of approaches described above is not a substitute for a CRT. Nonetheless, this strategy has at least two major strengths that can lay the foundations for a future CRT. First, the proposed investigations are not dependent on the uniform application of the intervention, which by nature will vary through time and space. Instead, an association between *Wolbachia* presence and proxies of DENV transmission (e.g., DENV seroconversion or occurrence of secondary cases around index cases) can be inferred dynamically from the spatiotemporal correlation between these factors. Second, comprehensive observation and detection of correlations between multiple environmental and biological factors will likely improve fundamental understanding of dengue epidemiology that will inform and underpin future trial designs. A multi-pronged approach would also help to evaluate potential impacts on other *Ae. aegypti*-borne arboviruses (e.g., chikungunya virus), and the likelihood of unexpected outcomes such as viral evolution to escape the inhibitory effects of *Wolbachia*, or other unanticipated, adverse events.

Measuring the epidemiological impact of a *Wolbachia* deployment to reduce DENV transmission is challenging. The intervention is not based on individuals, as a vaccine trial would be, but on populations defined by spatial areas. The fundamental test of the impact of the intervention is a comparison between areas where *Wolbachia*-infected mosquitoes are present versus areas where they are not (Figures 2, 3). Although limited dispersal of *Ae. aegypti*³⁸ and, therefore, spread of *Wolbachia*, is expected to maintain spatial delineation of the intervention, a buffer zone will be necessary to avoid unanticipated overlap between treatment and control areas. The intervention needs to be deployed over a large enough geographic area to ensure that a sufficient number of dengue cases (or absence of cases if the intervention is effective) is captured. Prior knowledge of the study area will help to assign intervention and control areas with similar baseline transmission trends. Virus importation into the intervention area (through human-mediated dispersal^{23,24}), which is likely to occur

and may reduce the signal-to-noise ratio, can be explored with geographic cluster studies and by accounting for movement of study subjects.

One advantage of our proposed approach is that interpretation of seroconversion data from a small-scale pediatric cohort can be enhanced by data from geographical cluster investigations, viral sequencing and virus detection in mosquitoes, collectively resulting in a body of evidence that could support continued development of *Wolbachia* as public health tool. In any case, virus importation by study participants exposed to infected mosquitoes outside of the treatment area would result in false positive cases in the *Wolbachia*-treated area and conservatively lead to an underestimation of efficacy. A true placebo treatment (i.e., release of *Wolbachia*-free mosquitoes) is not ethically possible. The human and mosquito samples can, however, be blinded prior to laboratory testing.

We have described a pragmatic approach for evaluation of novel entomological interventions for dengue control through a coordinated, cross-disciplinary, ecological study that combines several proxies of efficacy at the epidemiological, entomological and virological levels. It relies on a combination of methodologies that have been successfully used to monitor dengue epidemiological dynamics, as well as novel methodologies. Although this approach has no precedent for dengue, it has the potential to provide valuable intermediate evidence of efficacy that supports the *Wolbachia* methodology and justifies funding for a CRT or deployment.

Acknowledgements

We thank Stephanie James and Fil M. Randazzo for their insights, and two anonymous reviewers for helpful comments. This work was supported by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative of the Bill and Melinda Gates Foundation.

Contributors

LL wrote the first draft of the manuscript. All other authors contributed equally to edit the manuscript.

Conflicts of interest

We declare that we have no conflict of interest

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature* 2013; **496**: 504-7.
2. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. *N Engl J Med* 2012; **366**: 1423-32.
3. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and proposing solutions for control of the virus vector *Aedes aegypti*. *PLoS Med* 2008; **5**: e68.
4. McGraw EA, O'Neill SL. Beyond insecticides: new thinking on an ancient problem. *Nat Rev Microbiol* 2013; **11**: 181-93.
5. James S, Simmons CP, James AA. Ecology. Mosquito trials. *Science* 2011; **334**: 771-2.
6. Iturbe-Ormaetxe I, Walker T, O'Neill SL. *Wolbachia* and the biological control of mosquito-borne disease. *EMBO Rep* 2011; **12**: 508-18.
7. Hertig M, Wolbach SB. Studies on *Rickettsia*-like micro-organisms in insects. *J Med Res* 1924; **44**: 329-74.
8. Hilgenboecker K, Hammerstein P, Schlattmann P, Telschow A, Werren JH. How many species are infected with *Wolbachia*?--A statistical analysis of current data. *FEMS Microbiol Lett* 2008; **281**: 215-20.
9. Werren JH, Baldo L, Clark ME. *Wolbachia*: master manipulators of invertebrate biology. *Nat Rev Microbiol* 2008; **6**: 741-51.
10. Laven H. Eradication of *Culex pipiens fatigans* through cytoplasmic incompatibility. *Nature* 1967; **216**: 383-4.
11. Curtis CF. Population replacement in *Culex fatigans* by means of cytoplasmic incompatibility. 2. Field cage experiments with overlapping generations. *Bull World Health Organ* 1976; **53**: 107-19.
12. Baldini F, Segata N, Pompon J, Marcenac P, Robert Shaw W, Dabire RK, et al. Evidence of natural *Wolbachia* infections in field populations of *Anopheles gambiae*. *Nature Commun* 2014; **5**: 3985.

- 346 13. Xi Z, Khoo CC, Dobson SL. *Wolbachia* establishment and invasion in an *Aedes*
347 *aegypti* laboratory population. *Science* 2005; **310**: 326-8.
- 348 14. Ruang-Areerate T, Kittayapong P. *Wolbachia* transinfection in *Aedes aegypti*: a
349 potential gene driver of dengue vectors. *Proc Natl Acad Sci U S A* 2006; **103**: 12534-9.
- 350 15. McMeniman CJ, Lane AM, Fong AW, Voronin DA, Iturbe-Ormaetxe I, Yamada R, et
351 al. Host adaptation of a *Wolbachia* strain after long-term serial passage in mosquito cell lines.
352 *Appl Environ Microbiol* 2008; **74**: 6963-9.
- 353 16. McMeniman CJ, Lane RV, Cass BN, Fong AW, Sidhu M, Wang YF, et al. Stable
354 introduction of a life-shortening *Wolbachia* infection into the mosquito *Aedes aegypti*. *Science*
355 2009; **323**: 141-4.
- 356 17. Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu G, Pyke AT, Hedges LM, et al. A
357 *Wolbachia* symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and
358 *Plasmodium*. *Cell* 2009; **139**: 1268-78.
- 359 18. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F,
360 et al. Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue
361 transmission. *Nature* 2011; **476**: 454-7.
- 362 19. Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, et
363 al. The wMel *Wolbachia* strain blocks dengue and invades caged *Aedes aegypti* populations.
364 *Nature* 2011; **476**: 450-3.
- 365 20. Wolbers M, Kleinschmidt I, Simmons CP, Donnelly CA. Considerations in the design
366 of clinical trials to test novel entomological approaches to dengue control. *PLoS Negl Trop*
367 *Dis* 2012; **6**: e1937.
- 368 21. Harris AF, McKemey AR, Nimmo D, Curtis Z, Black I, Morgan SA, et al. Successful
369 suppression of a field mosquito population by sustained release of engineered male
370 mosquitoes. *Nature Biotechnol* 2012; **30**: 828-30.
- 371 22. Endy TP, Yoon IK, Mammen MP. Prospective cohort studies of dengue viral
372 transmission and severity of disease. *Curr Top Microbiol Immunol* 2010; **338**: 1-13.

- 373 23. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM,
374 Astete H, et al. House-to-house human movement drives dengue virus transmission. *Proc*
375 *Natl Acad Sci U S A* 2013; **110**: 994-9.
- 376 24. Stoddard ST, Morrison AC, Vazquez-Prokopec GM, Paz Soldan V, Kochel TJ, Kitron
377 U, et al. The role of human movement in the transmission of vector-borne pathogens. *PLoS*
378 *Negl Trop Dis* 2009; **3**: e481.
- 379 25. Yoon IK, Getis A, Aldstadt J, Rothman AL, Tannitisupawong D, Koenraadt CJ, et al.
380 Fine scale spatiotemporal clustering of dengue virus transmission in children and *Aedes*
381 *aegypti* in rural Thai villages. *PLoS Negl Trop Dis* 2012; **6**: e1730.
- 382 26. Reyes M, Mercado JC, Standish K, Matute JC, Ortega O, Moraga B, et al. Index
383 cluster study of dengue virus infection in Nicaragua. *Am J Trop Med Hyg* 2010; **83**: 683-9.
- 384 27. Rabaa MA, Ty Hang VT, Wills B, Farrar J, Simmons CP, Holmes EC. Phylogeography
385 of recently emerged DENV-2 in southern Viet Nam. *PLoS Negl Trop Dis* 2010; **4**: e766.
- 386 28. Raghwani J, Rambaut A, Holmes EC, Hang VT, Hien TT, Farrar J, et al. Endemic
387 dengue associated with the co-circulation of multiple viral lineages and localized density-
388 dependent transmission. *PLoS Pathog* 2011; **7**: e1002064.
- 389 29. Jarman RG, Holmes EC, Rodpradit P, Klungthong C, Gibbons RV, Nisalak A, et al.
390 Microevolution of dengue viruses circulating among primary school children in Kamphaeng
391 Phet, Thailand. *J Virol* 2008; **82**: 5494-500.
- 392 30. Rabaa MA, Klungthong C, Yoon IK, Holmes EC, Chinnawirotpisan P,
393 Thaisomboonsuk B, et al. Frequent in-migration and highly focal transmission of dengue
394 viruses among children in Kamphaeng Phet, Thailand. *PLoS Negl Trop Dis* 2013; **7**: e1990.
- 395 31. Barrera R, Mackay AJ, Amador M. An improved trap to capture adult container-
396 inhabiting mosquitoes. *J Am Mosq Control Assoc* 2013; **29**: 358-68.
- 397 32. Krockel U, Rose A, Eiras AE, Geier M. New tools for surveillance of adult yellow fever
398 mosquitoes: comparison of trap catches with human landing rates in an urban environment. *J*
399 *Am Mosq Control Assoc* 2006; **22**: 229-38.

33. Ritchie SA, Buhagiar TS, Townsend M, Hoffmann A, Van Den Hurk AF, McMahon JL, et al. Field validation of the gravid Aedes trap (GAT) for collection of *Aedes aegypti* (Diptera: Culicidae). *J Med Entomol* 2014; **51**: 210-9.
34. Vazquez-Prokopec GM, Galvin WA, Kelly R, Kitron U. A new, cost-effective, battery-powered aspirator for adult mosquito collections. *J Med Entomol* 2009; **46**: 1256-9.
35. Frentiu FD, Zakir T, Walker T, Popovici J, Pyke AT, van den Hurk A, et al. Limited dengue virus replication in field-collected *Aedes aegypti* mosquitoes infected with *Wolbachia*. *PLoS Negl Trop Dis* 2014; **8**: e2688.
36. Nguyen N, Thi Hue Kien D, Tuan T, Quyen N, Tran C, Vo Thi L, et al. Host and viral features of human dengue cases shape the population of infected and infectious *Aedes aegypti* mosquitoes. *Proc Natl Acad Sci U S A* 2013; **110**: 9072-7.
37. Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. *Hum Vaccin Immunother* 2013; **9**: 1587-90.
38. Harrington LC, Scott TW, Lerdthusnee K, Coleman RC, Costero A, Clark GG, et al. Dispersal of the dengue vector *Aedes aegypti* within and between rural communities. *Am J Trop Med Hyg* 2005; **72**: 209-20.

Figure Legends

Figure 1. Key dates in the development of *Wolbachia*-based dengue control strategies.

The timeline shows major achievements over the last century that have supported the development of *Wolbachia* as a dengue control tool.

Figure 2. Geographical cluster methodology. The central dot represents the home of a confirmed dengue case (orange: area with *Wolbachia*; green: area without *Wolbachia*).

People living within a 100-m radius (black dots) are screened for concomitant and/or secondary DENV infection (crosses denote homes of additional DENV-infected individuals).

Figure 3. Schematic representation of how *Wolbachia* intervention might change patterns of virus genetic diversity. Assuming that multiple lineages of various DENV

serotypes (colored dots) co-circulate prior to the intervention, a reduction in local DENV transmission is expected to result in a decrease in viral genetic diversity in the intervention area and a relative increase in the average dispersion distances.

Figure 1

Figure 2
Area with *Wolbachia*

Area without *Wolbachia*